Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-pulsed dendritic cell vaccine + interleukin-2
- Development stage
- Unknown
- Lead developer
- University of Michigan Rogel Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
This investigational combination therapy, developed by the University of Michigan Rogel Cancer Center, consists of an autologous tumor-pulsed dendritic cell vaccine and interleukin-2 (IL-2). The treatment involves harvesting a patient's own dendritic cells and exposing them in a laboratory to dead fragments (antigens) of the patient's specific tumor cells. These 'pulsed' dendritic cells are then re-injected into the patient to act as a vaccine, presenting tumor antigens to the immune system to sensitize and activate T-lymphocytes against the cancer. Interleukin-2 is administered concurrently as a cytokine adjuvant to enhance the activation, proliferation, and survival of these tumor-reactive T-cells. This approach is specifically being evaluated for its efficacy and safety in patients with metastatic colorectal cancer.
- Other names
- Autologous Tumor-Pulsed Dendritic Cell Vaccine with IL-2DC vaccine + IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on autologous tumor-pulsed dendritic cell vaccine + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-pulsed dendritic cell vaccine + interleukin-2.